Key Takeaways

Melanotan II is purported to create a tan, suppress appetite, and increase sexual response.
The evidence is narrower: a three-person study reported pigmentation, and two ten-person studies reported acute erections in men.
The molecule is not FDA-approved, nasal-spray use has not been clinically validated, a tan is not sunscreen, and FDA currently highlights both peptide-quality concerns and serious case reports.

‍

[Dorr et al., 1996; Wessells et al., 1998; FDA, 2026].

‍

Melanotan II: an unapproved, investigational synthetic cyclic alpha-melanocyte-stimulating-hormone analogue — canonical active-moiety sequence Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 — developed for melanocortin agonism but now circulating mainly as gray-market tanning injections and nasal sprays.

Overview

Melanotan II has more direct human exposure data than many peptides circulating in the gray market, but that fact is easy to overread. The same-molecule human record is a small 1996 pigmentation pilot in three healthy men and two acute crossover studies of ten men each with erectile dysfunction, all using subcutaneous research material. Those studies can support narrow statements about observed pigmentation, erections, and short-term adverse effects. They do not validate modern online vials, nasal sprays, cosmetic tanning regimens, chronic use, or long-term safety. [Dorr et al., 1996; Wessells et al., 1998; Wessells et al., 2000a]

The central scientific problem is nonselective melanocortin pharmacology. Melanotan II is a synthetic cyclic alpha-melanocyte-stimulating-hormone analogue that activates MC1R, MC3R, MC4R, and MC5R rather than a single clinically controlled target. MC1R activation explains the pigmentation signal, while central melanocortin pathways help explain appetite, yawning, nausea, sexual desire, and erection findings. That mechanistic breadth means the market cannot borrow the safety or efficacy of selective, FDA-approved melanocortin drugs such as afamelanotide, bremelanotide, or setmelanotide. [Schioth et al., 1997; FDA, 2019; FDA, 2024; FDA, 2026]

Melanotan II is not FDA-approved for any indication. It is not listed in FDA's active 503A Category 1, Category 2, or Category 3 tables as of the May 14, 2026 update; instead, FDA's safety-risk page places it in the section for bulk drug substances nominated but withdrawn. FDA cites potential immunogenicity from aggregation or peptide-related impurities and published case reports involving melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, and priapism. FDA has separately announced a future PCAC meeting before the end of February 2027 to discuss Melanotan II and four other substances for possible inclusion on the 503A bulks list. That advisory process is not new-drug approval. [FDA, 2026]

The dominant current use case is a consumer market built around tanning injections, nasal sprays, appetite suppression, sexual effects, body-image optimization, and social-media stack culture. Product quality is a separate safety problem: a laboratory analysis of online products found that vials labeled as containing 10 mg held 4.32 to 8.84 mg and that some contained measurable unknown impurities. [Breindahl et al., 2015; Gilhooley et al., 2021; Orr et al., 2025; Allure, 2026; The Guardian, 2026]

What it is

Melanotan II, usually abbreviated MT-II, MT2, or Melanotan 2, is a laboratory-designed cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. PubChem lists the active moiety as C50H69N15O9 with a molecular weight near 1024.2 Da. [Dorr et al., 1996; PubChem, 2026]

The chemistry was designed to increase stability and potency relative to endogenous alpha-MSH, not to reproduce the hormone in a physiologic pulse. Receptor-binding work describes MT-II as a high-affinity, nonselective agonist at human MC1R, MC3R, MC4R, and MC5R. MT-II is a broad synthetic melanocortin agonist, not simply "more melanin" in peptide form. [Schioth et al., 1997; Habbema et al., 2017]

The evidence boundary is strict. Human data from Melanotan II belong to the exact subcutaneous research material used in those studies. Afamelanotide implant data belong to afamelanotide; bremelanotide data belong to bremelanotide; setmelanotide data belong to setmelanotide. A nasal spray, online vial, prefilled pen, combination stack, or reformulated salt cannot inherit another product's evidence merely because the names share "melanotan" or the pathway shares melanocortin receptors. [FDA, 2019; FDA, 2024; FDA, 2026]

Material	What it is	Why it cannot be collapsed into "Melanotan II"
Endogenous alpha-MSH	A 13-amino-acid POMC-derived melanocortin peptide involved in pigmentation and other physiology.	Native physiology does not establish the safety, exposure, or therapeutic value of an exogenous cyclic analogue. [Habbema et al., 2017]
Afamelanotide / Melanotan I / SCENESSE	A linear alpha-MSH analogue developed through a formal drug program; SCENESSE is an FDA-approved implant for adults with erythropoietic protoporphyria.	An approved implant, selective clinical program, and narrow indication do not transfer to Melanotan II injections or sprays. [FDA, 2024]
Bremelanotide / PT-141 / VYLEESI	A related cyclic melanocortin agonist developed from the sexual-response lineage and FDA-approved for acquired, generalized HSDD in certain premenopausal women.	VYLEESI efficacy, dosing, and safety do not prove Melanotan II efficacy in women, men, or sexual-performance settings. [FDA, 2019]
Setmelanotide / IMCIVREE	A distinct MC4 receptor agonist approved for chronic weight management in specific rare genetic, syndromic, or acquired hypothalamic obesity populations.	Its receptor targeting and rare-disease trials do not validate Melanotan II as a general weight-loss peptide. [FDA, 2026]
Gray-market vial or prefilled pen	An online product often labeled for research use, reconstitution, or subcutaneous self-injection.	Label identity, content, sterility, endotoxin, and dose accuracy are not established by the name on the vial. [Breindahl et al., 2015; Hadeler et al., 2022]
Nasal tanning spray	A consumer-market intranasal presentation commonly advertised as easier or less invasive than injection.	No controlled same-molecule human intranasal efficacy, PK, or long-term safety program was identified; route convenience is not route validation. [LegitScript, 2024; TGA, 2025]

How it's proposed to work

The best-supported mechanistic backbone comes from melanocortin receptor pharmacology. MT-II binds multiple melanocortin receptor subtypes rather than acting as a selective MC1R-only skin drug. MC1R activation on melanocytes increases cAMP-linked melanogenic signaling and helps explain the pigmentation observed in the three-person pilot. [Schioth et al., 1997; Dorr et al., 1996]

The second major layer is central melanocortin signaling. MC3R/MC4R-rich neural pathways are implicated in energy balance, appetite, autonomic behavior, and sexual response. The combination of erections, increased sexual desire, yawning, nausea, and decreased appetite is consistent with broad central melanocortin agonism. [Wessells et al., 1998; Wessells et al., 2000b; Wessells et al., 2003]

Animal work extends the map into anorexia, thermogenesis, hypothermia, mast cell/histamine signaling, and peripheral nerve biology. Diet-induced obese rats retained anorexic and thermogenic responses to MT-II, and a separate mouse study linked MT-II-induced hypothermia to mast cells and histamine H1 receptors. Another rat study reported peripheral nerve-regeneration and neuroprotective findings. These are distinct preclinical experiments, not a single human "metabolic optimization" mechanism. [Li et al., 2004; Jain et al., 2018; Ter Laak et al., 2003]

Common forms in circulation

FDA's current safety-risk page uses the name "Melanotan II" as a bulk drug substance and places it in the nominated-but-withdrawn section. FDA does not thereby endorse a free base, acetate salt, injectable vial, nasal spray, dose, or indication. [FDA, 2026]

The live consumer market is broader: lyophilized vials reconstituted for subcutaneous self-injection, prefilled pens, intranasal tanning sprays, and products framed as "research use only." [Breindahl et al., 2015; Gilhooley et al., 2021; LegitScript, 2024; The Guardian, 2026]

Nasal products deserve explicit separation because the route sounds lower risk. The published human efficacy studies reviewed here used subcutaneous research material, not intranasal sprays. A spray may remove a needle, but it does not remove systemic melanocortin pharmacology, dosing uncertainty, mucosal absorption variability, contamination risk, or the absence of long-term data. [Dorr et al., 1996; Wessells et al., 1998; TGA, 2025]

Names and aliases

Names and aliases include Melanotan II, melanotan-II, Melanotan 2, MT-II, MT2, "tanning peptide," "tan jab," "nasal tanner," "vacation peptide," and "Barbie drug." Copy must also guard against confusion with melatonin, the unrelated sleep-associated hormone, and with Melanotan I/afamelanotide. [PubChem, 2026; FDA, 2019; FDA, 2024; Orr et al., 2025]

Regulatory status

Melanotan II has no FDA-approved human indication. It is not an approved tanning drug, erectile-dysfunction drug, female-sexual-dysfunction drug, obesity drug, or dermatologic prevention product. FDA's current compounding-risk page identifies MT-II under "bulk drug substances nominated but withdrawn" and states that compounded products may pose immunogenicity risk for certain routes because of aggregation or peptide-related impurities. FDA also cites published case reports involving melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, and priapism. [FDA, 2026]

As of FDA's May 14, 2026 503A category update, Melanotan II does not appear in active Category 1, active Category 2, or Category 3. Its presence on the separate safety-risk page reflects the withdrawn nomination and the concerns FDA had identified; it is not a permissive category. [FDA, 2026]

International regulators are similarly cautionary. Australia's TGA warns that melanotan products are not approved tanning agents, that pigmentation is not a substitute for sunscreen, and that unregistered products may be supplied in injection, spray, tablet, or cream forms. In May 2026, TGA announced 27 paid infringement notices totaling AUD 101,412 over alleged unlawful supply of Melanotan II and stated that no MT-II product was on the Australian Register of Therapeutic Goods. [TGA, 2025; TGA, 2026]

FDA has announced that a Pharmacy Compounding Advisory Committee meeting will occur before the end of February 2027 and will discuss Melanotan II, Cathelicidin LL-37, GHK-Cu, Dihexa acetate, and PEG-MGF for potential inclusion on the 503A bulks list. FDA states that advisory committees provide independent expert advice and make non-binding recommendations. A favorable discussion would not itself approve MT-II, validate a tanning or sexual-function claim, authorize every compounded presentation, establish a dose, or convert gray-market products into FDA-reviewed drugs. [FDA, 2026]

Human evidence

Study	Design and population	What was reported	Main limit
Dorr et al., 1996	Pilot Phase I; three healthy men; single-blind alternating saline and subcutaneous MT-II exposure.	Two participants showed measurable/visible increased pigmentation after the dosing period; adverse effects included nausea, yawning/stretching, spontaneous erections, somnolence, and fatigue.	Too small for efficacy estimation, demographic generalization, chronic safety, route comparison, or product-level recommendations.
Wessells et al., 1998	Double-blind, placebo-controlled crossover; ten men with psychogenic erectile dysfunction; acute subcutaneous administration.	Clinically apparent erections occurred in eight of ten men, and objective rigidity duration exceeded placebo; nausea, yawning, stretching, and decreased appetite were reported.	Does not establish long-term ED treatment, repeated-use safety, female sexual effects, or superiority to approved therapies.
Wessells et al., 2000a	Double-blind crossover; ten men with organic erectile-dysfunction risk factors; acute subcutaneous administration.	Active injections produced more subjective erections and much longer periods of high tip rigidity than placebo; severe nausea occurred after four of nineteen active injections.	Still a tiny acute study; no chronic treatment outcome, validated commercial product, or broad sexual-wellness claim.

The pigmentation and erection signals are sufficiently direct to say that MT-II can produce those effects under the studied conditions. The studies are not sufficiently large or long to estimate a commercial benefit-risk profile, define a chronic regimen, characterize uncommon harms, compare routes, or support broad populations. [Dorr et al., 1996; Wessells et al., 1998; Habbema et al., 2017]

The male erectile-response data also cannot be rewritten as a generic libido claim. Objective rigidity and patient-reported desire were acute endpoints in small male cohorts. Bremelanotide's later FDA approval for a specific HSDD population shows that melanocortin sexual pharmacology can be clinically developed, but it does not retroactively validate MT-II for that use. [Wessells et al., 2000a; Wessells et al., 2000b; FDA, 2019]

Safety

Human therapeutic safety has not been established. The small controlled studies captured frequent, mechanism-consistent acute effects but were incapable of detecting uncommon or delayed harms. Post-market-like information comes from case reports, poison/toxicology literature, dermatology observations, and unregulated-product studies rather than a standardized surveillance program. [FDA, 2026; Habbema et al., 2017]

Safety domain	What has been reported	What it supports	What it does not settle
Expected acute melanocortin effects	Nausea, yawning/stretching, decreased appetite, fatigue/somnolence, flushing-like symptoms, spontaneous erections.	Observed in the tiny controlled human studies.	Frequency and severity in modern consumer use are not known. [Dorr et al., 1996; Wessells et al., 1998; Wessells et al., 2000a]
Priapism	Prolonged painful erections requiring urgent or surgical management have been reported.	Multiple case reports align with the known pro-erectile pharmacology.	Case reports do not establish incidence, but they make "libido side effect" language materially inadequate. [Devlin et al., 2013; Dreyer et al., 2019; Mallory et al., 2021]
Systemic toxicity and rhabdomyolysis	A published case described sympathomimetic-type systemic toxicity, rhabdomyolysis, and renal dysfunction after injection.	Supports a serious overdose/misuse signal cited by FDA.	Does not establish the risk at any specific verified dose or product. [Nelson et al., 2012; FDA, 2026]
Neurologic toxicity / PRES	Posterior reversible encephalopathy syndrome was reported after melanotan exposure.	Supports a serious neurologic case-report signal cited by FDA.	Cannot quantify population risk or prove causality by itself. [Kaski et al., 2013; FDA, 2026]
Renal/vascular events	Renal infarction has been reported in temporal association with MT-II use.	Supports vascular and renal caution in the adverse-event register.	A single case cannot define mechanism or incidence. [Peters et al., 2020]
Pigmentary lesions and melanoma	Case reports describe eruptive or changing nevi and melanoma in situ or melanoma after use; current clinicians also report abnormal mole presentations.	Supports dermatologic surveillance concern and FDA's case-report warning.	Case reports cannot establish that MT-II caused melanoma, especially when UV or sunbed exposure and baseline risk coexist. [Ong and Bowling, 2012; Hjuler and Lorentzen, 2014; FDA, 2026; ABC News, 2026]
Product-content and contamination risk	Online vials have shown underfill, variable peptide content, and unknown impurities; users describe self-reconstitution and polypharmacy.	Supports a separate supply-chain hazard beyond the active molecule itself.	A clean certificate, brand name, or "research grade" label is not proof of sterile pharmaceutical quality. [Breindahl et al., 2015; Gilhooley et al., 2021; Hadeler et al., 2022]

It is supportable to say that FDA cites melanoma case reports and that dermatologists have reported rapidly changing or atypical nevi after use. It is not supportable to assign a causal risk ratio or say that MT-II definitively causes melanoma from those reports alone. [FDA, 2026; Ong and Bowling, 2012; Hjuler and Lorentzen, 2014; ABC News, 2026]

Breindahl and colleagues tested vials labeled as 10 mg and found 4.32 to 8.84 mg of MT-II, with unknown impurities comprising 4.1% to 5.9% in products from two shops. That means a consumer may face uncertainty in identity, strength, impurities, sterility, endotoxin, reconstitution, and calculation before pharmacology begins. [Breindahl et al., 2015]

Purported benefits, by evidence

Purported benefit	What the evidence supports	What it does not support	Source
Skin pigmentation / tanning	A three-man pilot reported measurable and visible pigmentation in two participants after repeated subcutaneous MT-II exposure.	Does not support "clinically proven tanning treatment," predictable cosmetic results, an approved regimen, or long-term safety.	[Dorr et al., 1996]
UV protection / sunscreen substitute	A tan provides only limited natural protection; FDA describes a tan as roughly SPF 2 to 4, far below recommended sun protection.	Does not support "protects against UV," "replaces sunscreen," or "prevents sun damage."	[FDA, 2026; TGA, 2025]
Skin-cancer prevention	Early formulation work discussed MT-II as a potential chemopreventive concept because melanogenesis might reduce UV injury.	Does not support "prevents melanoma" or "reduces skin-cancer risk." FDA cites melanoma case reports, and no prevention outcome trial was identified.	[Lan et al., 1994; FDA, 2016; FDA, 2026]
Erection initiation in men with ED	Two ten-man studies reported substantially more and longer erectile responses after subcutaneous MT-II than placebo in psychogenic and organic ED populations.	Does not support "approved ED treatment," durable benefit, routine repeated use, or a known benefit-risk profile.	[Wessells et al., 1998; Wessells et al., 2000a]
Female sexual desire / HSDD	The melanocortin pathway is clinically relevant to sexual desire because the related drug bremelanotide is FDA-approved for a specific HSDD population.	Does not support "Melanotan II treats low desire" or borrowing VYLEESI trial results, label, dosing, or safety.	[FDA, 2019]
Appetite suppression / weight loss	Rodent studies reported anorexic and thermogenic responses, and decreased appetite appeared among acute human adverse effects.	Does not support "weight-loss peptide," durable fat loss, obesity treatment, or safe appetite control in humans.	[Li et al., 2004; Wessells et al., 1998]
Nerve regeneration / neuroprotection	A rat study reported peripheral nerve-regeneration and neuroprotective findings after MT-II.	Does not support human neuropathy treatment, recovery, cognitive enhancement, or a clinically validated neuroprotective therapy.	[Ter Laak et al., 2003]
Safety because it mimics a natural hormone	Structural similarity to alpha-MSH explains the biological story and receptor activity.	Does not establish safe exposure, selective targeting, product quality, route equivalence, or freedom from serious adverse events.	[Schioth et al., 1997; FDA, 2026; Habbema et al., 2017]

Key literature

Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777-1784. The foundational pigmentation pilot study.

Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction. J Urol. 1998;160(2):389-393. Direct evidence for acute erection initiation in ten men.

Schioth HB, Muceniece R, Mutulis F, Bouifrouri AA, Mutule I, Wikberg JES. Selectivity of cyclic [D-Nal7] and [D-Phe7] substituted MSH analogues for the melanocortin receptor subtypes. Peptides. 1997;18(7):1009-1013. Nonselective high-affinity activity across human MC1R, MC3R, MC4R, and MC5R.

Breindahl T, Evans-Brown M, Hindersson P, McVeigh J, Bellis M, Stensballe A, Kimergard A. Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. Drug Test Anal. 2015;7(2):164-172. Direct evidence of underfilled vials, variable MT-II content, and unknown impurities in online products.

Habbema L, Halk AB, Neumann M, Bergman W. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. Int J Dermatol. 2017;56(10):975-980. A consolidated map of unregulated use, pigmentation changes, systemic adverse effects, and evidence limitations.

References

U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current April 22, 2026.
U.S. Food and Drug Administration. Meeting of the Pharmacy Compounding Advisory Committee. Content current April 15, 2026.
U.S. Food and Drug Administration. Risks of Tanning. Accessed July 2026.
U.S. Food and Drug Administration. VYLEESI (bremelanotide injection) Prescribing Information. Initial U.S. approval 2019.
U.S. Food and Drug Administration. SCENESSE (afamelanotide) implant Prescribing Information. Revised 2024.
U.S. Food and Drug Administration. IMCIVREE (setmelanotide) injection Prescribing Information. Revised 2026.
Therapeutic Goods Administration. Don't risk using tanning products containing melanotan. January 24, 2025.
Therapeutic Goods Administration. Individual issued 27 infringement notices for allegedly supplying Melanotan II. May 21, 2026.
World Anti-Doping Agency. International Standard: 2026 Prohibited List. Effective January 1, 2026.
Allure. No, You Shouldn't Inject a Peptide to Get Tan. July 9, 2026.
ABC News Australia. Abnormal moles seen developing in patients chasing perfect suntan by using peptide melanotan-II. June 5, 2026.
The Guardian. Unlicensed weight-loss drugs marketed on social media as "prizes." February 5, 2026.

Melanotan II